Lck抑制剂III用途
本网站展示的所有产品仅用作科学研究,不可食用,不可用于人体或动物的临床诊断和治疗。
Lck抑制剂III是一种可渗透细胞的,靶向ATP结合位点的三取代嘧啶,起淋巴细胞特异性激酶(Lck)抑制剂的作用(IC | 50 | = 867 nM; [ATP] = 10μM)。据报道,在CD3交联和PMA刺激下,Jurkat E6-1 T细胞系(IC | 50 | = 1.27μM)可以阻断IL-2的释放。尽管其效力不及Lck抑制剂II强,但其水溶性却大大提高(在50 mM PBS中,pH 7.4,离子强度0.15 M,27μg/ ml)。 Lck Inhibitor III is a cell-permeable, ATP binding site-targeting, tri-substituted pyrimidine that acts as a lymphocyte specific kinase (Lck) inhibitor (IC|50|= 867 nM; [ATP] = 10 μM). Has been reported to block IL-2 release in Jurkat E6-1 T cell line (IC|50|= 1.27 μM) stimulated by CD3 cross-linking and PMA. Although less potent than Lck Inhibitor II, it exhibits much improved aqueous solubility (27 μg/ml in 50 mM PBS, pH 7.4, ionic strength 0.15 M).
|